DENVER, Colo. (247marketnews.com) -- HeartBeam (NASDAQ:BEAT) scored a significant regulatory catalyst as the U.S. FDA granted Breakthrough Device Designation to the HeartBeam System for its potential use in assessing suspected heart attacks outside the hospital. The designation gives the company prioritized interaction with the FDA as it works toward a pivotal study and potential expansion of the device’s indication.
The opportunity is centered on HeartBeam’s proprietary 3D ECG technology, which captures cardiac electrical signals from three non-coplanar directions and synthesizes them into a 12-lead ECG representation. The company is attempting to address a major gap in acute cardiac care: the period between the onset of symptoms and arrival at a medical facility. HeartBeam says more than 20 million U.S. adults are at elevated risk of heart attack and estimates the myocardial infarction opportunity at approximately $15 billion within a broader cardiac platform opportunity exceeding $40 billion.
The regulatory catalyst arrives as HeartBeam advances its clinical program. The company completed enrollment in its 134-patient ALIGN-ACS pilot study ahead of schedule, with results slated for presentation at TCT 2026. It has also surpassed 75% enrollment in the 500-patient HEADSTART-ACS study in Indonesia. Those studies are intended to inform the design of a U.S. pivotal trial and the eventual FDA pathway for a heart-attack assessment indication.
“One of the biggest gaps in heart attack care today occurs before the patient ever arrives at the hospital,” said cardiologist Tony Das, M.D. “HeartBeam’s technology has the potential to address this gap by providing timely access to clinical-grade ECG data outside the hospital, which could enable earlier MI intervention.” HeartBeam founder and President Branislav Vajdic, Ph.D., called the Breakthrough designation an “important milestone” and said the company’s heart-attack detection program is now its “top strategic priority.”
There is already a commercial foundation beneath the larger heart-attack opportunity. HeartBeam received FDA clearance for its 12-lead ECG synthesis software for arrhythmia assessment in December 2025 and has begun a limited commercial launch through preventive and concierge cardiology practices. The company has also developed a working prototype of an on-demand 12-lead ECG patch targeting the ambulatory cardiac monitoring market.
The setup is increasingly catalyst-driven, with Breakthrough Device Designation, upcoming ALIGN-ACS data, HEADSTART-ACS progress, FDA discussions around the pivotal study and the potential expansion from arrhythmia assessment into heart-attack assessment.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.